Everyone is on the lookout for cheap shares. But sometimes stocks are cheap for a reason, and that’s why it pays us to really do our research.
So let’s have a look at the beaten-down shares bought by investors on the Hargreaves Lansdown platform last week. Should I add them to my own portfolio?
Glencore
Glencore (LSE:GLEN) is on something of a bull run — the trading and mining giant is up a phenomenal 43% over 12 months. The stock has defied concerns around a weakening global economy, and surged in the autumn.
The Swiss-headquarted firm was on track to deliver record profits on the back of high oil and coal prices in 2022 — and it probably will. Earnings before interest and tax (EBIT) in the first half reached $3.7bn. Glencore’s autumn surge is also in spite of the firm posting sharp declines in the output of several industrial and precious metals in 2022.
And Glencore currently trades with a price-to-earnings (P/E) ratio of six. That’s pretty cheap.
So should I invest?
I see Glencore as a solid investment for the long run, but I don’t want to buy during a bull run. Its main products include copper, cobalt, zinc, nickel and ferroalloys. Ferroalloys and copper are integral to infrastructure development — something we will likely see a lot more of in the next decade.
Meanwhile, cobalt, zinc and nickel have seen demand surge due to the electrification agenda. On average, EVs need 39.9kg of nickel and 13.3kg of cobalt per car.
My issues are the recent surge and concerns about a global recession in 2022 — this would have a negative impact on resource prices. As such, I’m not buying just yet.
Dr Martens
Dr Martens (LSE:DOCS) shares collapsed last week, falling 20% when the market opened on 19 January. The fall came after the company warned that profits will be lower than expected this year, due to problems with its US operations.
But last week, it was also the fifth most bought stock in terms of share quantity. In fact, Dr Martens shares accounted for 1.2% of all shares bought on the Hargreaves platform.
Shares in the fashionable bootmaker have now fallen by over 65% since its January 2021 flotation. It’s also down 59% over 12 months.
Due to its US challenges, the firm now expects full-year revenue growth of 11-13% and earnings before interest, tax, depreciation and amortisation of between £250m and £260m. It had previously guided towards revenue growth in the high teens.
Dr Martens currently trades with a P/E of around 8. That’s certainly not expensive, and in-demand brands tend to trade with higher multiples.
Broadly, I think it’s a brand with a positive future, and near-term performance could be lifted by China’s reopening.
However, I’m a little cautious given the two profit downgrades and the volatility of the stock. I’m keeping a close eye on this one, but I’m not buying yet.
The post Cheap shares Hargreaves Lansdown investors have been buying. Should I join them? appeared first on The Motley Fool UK.
Should you invest £1,000 in Dr. Martens Plc right now?
When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Dr. Martens Plc made the list?
See the 6 stocks
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
2 FTSE shares I’m poised to pounce on
UK shares: 2 FTSE retail stocks to buy and 2 to avoid in February
Dividend shares: 2 FTSE 100 miners to buy for massive passive income
2 cheap UK stocks Hargreaves Lansdown investors have been buying! Should I join in?
8.3% and 5.5% dividend yields! Should I buy these cheap FTSE 100 income stocks?
James Fox has positions in Hargreaves Lansdown Plc. The Motley Fool UK has recommended Hargreaves Lansdown Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.